The story of the erectile dysfunction drug presents a complex picture for shareholders. While the initial introduction generated massive returns, the end of its intellectual property protection opened the floodgates to https://guidemysocial.com/story7141182/sildenafil-and-the-pharmaceutical-industry-a-risky-bet